de la Fuente, Josu, Merx, Kirsten, Steer, E. Joanna, Müller, Martin, Szydlo, Richard M., Maywald, Ole, Berger, Ute, Hehlmann, Rüdiger, Goldman, John M., Cross, Nicholas C.P., Melo, Junia V. and Hochhaus, Andreas (2001) ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood, 98 (9), 2879-2880. (doi:10.1182/blood.V98.9.2879).
Abstract
Hydroxyurea (HU) has been used for more than 10 years in children severely affected with sickle cell disease (SCD) to reduce the number of painful episodes. Short- to medium-term tolerance of the drug is good.1-3 Concern remains, however, about the long-term safety of the drug and, in particular, its leukemogenic potential. Leukemia has been reported in myelodysplastic syndromes after at least 3 to 4 years of exposure to the drug,4-5 so only long-term studies including significant numbers of patients can resolve concern for SCD. So far, 3 studies on long-term effects of HU in SCD children have been published (Table 1).6-8
This record has no associated files available for download.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.